Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $5.56 Analyst target: $15.40 Upside: 176.98%
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.